- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05293470
A Post Marketing Surveillance on Piqray in Korea
November 20, 2023 updated by: Novartis Pharmaceuticals
A Post Marketing Surveillance on Piqray (Alpelisib) in Korea
This is a prospective, multicenter, open-label, non-comparative, non-interventional, observational study to assess te safety and effectiveness of Piqray in the real-world setting
Study Overview
Detailed Description
The observation duration will be up to 24 weeks after enrollment, which is sufficient to provide adequate information about the safety and effectiveness of Piqray.
If the subject does not return for a follow-up visit or stops taking Piqray for any reason, all data collected until the date of the last contact of the subject will be used.
Patients will be followed up (safety follow up) for 30 days afetr either 24 weeks-treatment or early withdrawal.
Study Type
Observational
Enrollment (Estimated)
900
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Busan, Korea, Republic of, 48108
- Recruiting
- Novartis Investigative Site
-
Busan, Korea, Republic of, 602-030
- Recruiting
- Novartis Investigative Site
-
Daejeon, Korea, Republic of, 302-241
- Recruiting
- Novartis Investigative Site
-
Jeollanam, Korea, Republic of, 519763
- Recruiting
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 02841
- Recruiting
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 06273
- Recruiting
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 158-710
- Recruiting
- Novartis Investigative Site
-
-
Chungcheongnam Do
-
Cheonan Si, Chungcheongnam Do, Korea, Republic of, 31116
- Recruiting
- Novartis Investigative Site
-
-
Gyeonggi Do
-
Deogyang Gu Goyang Si, Gyeonggi Do, Korea, Republic of, 10475
- Recruiting
- Novartis Investigative Site
-
Suwon si, Gyeonggi Do, Korea, Republic of, 16499
- Recruiting
- Novartis Investigative Site
-
-
Seoul
-
Songpa-gu, Seoul, Korea, Republic of, 138-736
- Recruiting
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients who are going to receive Piqray per locally approved label are eligible and will be prescribed with Piqray under routine medical practice.
Description
Inclusion Criteria:
Subjects eligible for this study must meet all of the following criteria:
- Postmenopausal women and men who have a confirmed diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutated, advanced or metastatic breast cancer.
- Patients who have progressed on prior endocrine based therapy and are going to start Piqray treatment for the first time in accordance with the locally approved label.
- Patients who are willing to provide written informed consent
Exclusion Criteria:
Subjects eligible for this study must not meet the following criteria:
Patients with contraindication according to prescribing information for Piqray in Korea.
- Severe hypersensitivity to Piqray or to any of its components
- Female subjects who are pregnant and nursing (lactating)
- Patients who are sexually active but not willing to follow contraceptive precautions during taking Piqray.
- Participants who receive or are going to receive any investigational medicine during surveillance period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Piqray
Patients prescribed with Piqray
|
There is no treatment allocation.
Patients administered Piqray by prescription will be enrolled.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of AEs
Time Frame: 24 weeks
|
Incidence of AEs, including SAEs and ADRs
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rates (ORRs)
Time Frame: Up to 24 weeks
|
Objective response rates (ORRs).
ORR is defined as the proportion of treated patients who achieve a best overall response (BOR) of partial response (PR) or complete response (CR) according to the response evaluation criteria in solid tumors (RECIST) version 1.1.
|
Up to 24 weeks
|
Prescription dose of Piqray in combination with fulvestrant
Time Frame: Up to 24 weeks
|
Prescription dose of Piqray in combination with fulvestrant
|
Up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 29, 2022
Primary Completion (Estimated)
May 12, 2027
Study Completion (Estimated)
May 12, 2027
Study Registration Dates
First Submitted
March 15, 2022
First Submitted That Met QC Criteria
March 15, 2022
First Posted (Actual)
March 24, 2022
Study Record Updates
Last Update Posted (Actual)
November 21, 2023
Last Update Submitted That Met QC Criteria
November 20, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CBYL719CKR01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Piqray
-
Novartis PharmaceuticalsRecruiting
-
University of Kansas Medical CenterGilead Sciences; Novartis PharmaceuticalsRecruitingBreast CancerUnited States
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
Borstkanker Onderzoek GroepNovartis Pharma B.V.; BOOG Study CenterRecruitingNeoplasm, Breast | Congenital, Familial and Genetic DisordersNetherlands
-
Columbia UniversityCompletedInsulin Resistance | Dyslipidemias | HyperinsulinemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States
-
Priyanka SharmaNovartis PharmaceuticalsCompletedBreast CancerUnited States
-
Columbia UniversityUniversity of California, BerkeleyRecruitingInsulin Resistance | Prediabetic State | Overweight and Obesity | Non-Alcoholic Fatty Liver DiseaseUnited States
-
GOG FoundationNovartisRecruitingEndometroid Endometrial CancerUnited States
-
Stemline Therapeutics, Inc.RecruitingBreast Cancer | Metastatic Breast CancerUnited States